Indication
Infants with very high risk KMT2A B-ALL
1 clinical trial
1 product
Clinical trial
CD19-Directed Chimeric Antigen Receptor CD19 Redirected Autologous T Cells (CART19) for Orphan Indications of Pediatric B Cell Acute Lymphoblastic Leukemia (B ALL)Status: Recruiting, Estimated PCD: 2028-03-10
Product
Murine CART19